Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2178876 | 0.90 | KCNA3 (0.34) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL2180120 | 0.86 | SMN1; SMN2 (0.34) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL2179615 | 0.75 | KCNA3 (0.32) | — | |
| SCHEMBL2179854 | 0.75 | SMN1; SMN2 (0.36) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL3754173 | 0.75 | KCNA3 (0.35) | — | |
| SCHEMBL3761724 | 0.71 | KCNA3 (0.37) | — | |
| SCHEMBL1543309 | 0.71 | GCGR (0.37) | L3MBTL1SMN1; SMN2 | |
| SCHEMBL3759772 | 0.69 | KCNA3 (0.36) | — | |
| SCHEMBL2178762 | 0.69 | KCNA3 (0.35) | — | |
| SCHEMBL3764771 | 0.69 | KCNA3 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507539-B2 | Potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2013-08-13 | — | — | US | disclosed |
| US-8507539-B2 | Potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2013-08-13 | — | — | US | disclosed |
| US-8507539-B2 | Potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2013-08-13 | — | — | US | disclosed |
| US-20110166130-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2011-07-07 | — | — | US | disclosed |
| US-20110166130-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2011-07-07 | — | — | US | disclosed |
| US-20110166130-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2011-07-07 | — | — | US | disclosed |
| EP-2303850-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | Bionomics Limited (AU) | 2011-04-06 | — | — | EP | disclosed |
| WO-2009149508-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009149508-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166130-A1 | NOVEL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | KCNA3, KCNB1, KCNK3 | L3MBTL1 3853/4885SMN1; SMN2 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.